High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa.

• Status: Not yet recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the efficacy and safety of alternative magnesium sulfate regimens when used as single agent tocolytic therapy for prevention of preterm labour in patients with symptomatic placenta previa and subsequent changes in the cervical length .

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

1. Singleton pregnancy.

2. Gestational age between 28 weeks to 37 weeks.

3. Patients presented to the hospital with per vaginal bleeding and in whom a clinical diagnosis of placenta previa is confirmed by trans vaginal ultrasound.

4. Placenta previa with preterm uterine contractions (< 3 contractions in 10 minutes)

5. Ability to provide informed consent.

Exclusion Criteria:

1. Placental abruption .

2. Women with placenta previa and severe attack of bleeding need immediate termination

3. Clinical criteria of intra uterine infection.

4. IUGR.

5. Fetal anomalies.

6. Fetal distress.

7. IUFD.

8. PROM

9. High order multiple pregnancies.

10. Treatment with any tocolytic agent before maternal transport.

11. Inability or refusal to provide informed consent.

12. Women with any contraindication for use of magnesium sulfate as patients with renal failure.

13. Patients with bleeding disorder or on anticoagulant therapy .